Skip to main content

Advertisement

SpringerLink
Log in

Understanding cancer from the stem cells up

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

A new study that uses an integrated single-cell transcriptomics approach to characterize cancer stem cell populations during treatment with molecularly targeted therapies offers insights into disease evolution and points to new therapeutic targets.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: The dynamics of cancer stem cell selection and evolution on targeted therapy.

References

  1. Pattabiraman, D.R. & Weinberg, R.A. Nat. Rev. Drug Discov. 13, 497–512 (2014).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Valent, P. et al. Nat. Rev. Cancer 12, 767–775 (2012).

    Article  CAS  PubMed  Google Scholar 

  3. Giustacchini, A. et al. Nat. Med. 23 692–702 (2017).

    Article  CAS  PubMed  Google Scholar 

  4. O'Hare, T., Zabriskie, M.S., Eiring, A.M. & Deininger, M.W. Nat. Rev. Cancer 12, 513–526 (2012).

    Article  CAS  PubMed  Google Scholar 

  5. Hochhaus, A. et al. N. Engl. J. Med. 376, 917–927 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Corbin, A.S. et al. J. Clin. Invest. 121, 396–409 (2011).

    Article  CAS  PubMed  Google Scholar 

  7. Ellsworth, D.L. et al. Clin. Transl. Med. 6, 15 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Warfvinge, R. et al. Blood 129, 2384–2394 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Hanahan, D. & Coussens, L.M. Cancer Cell 21, 309–322 (2012).

    Article  CAS  PubMed  Google Scholar 

  10. The Cancer Genome Atlas Research Network. Nature 511, 543–550 (2014).

  11. Cancer Genome Atlas Research N. Engl. J. Med. 368, 2059–2074 (2013).

  12. Maheswaran, S. & Haber, D.A. Curr. Opin. Genet. Dev. 20, 96–99 (2010).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. and in the Division of Hematology and Medical Oncology, Christopher A. Eide and Brian J. Druker are at the Howard Hughes Medical Institute Portland, Oregon, USA, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.,

    Christopher A Eide & Brian J Druker

Authors
  1. Christopher A Eide
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian J Druker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian J Druker.

Ethics declarations

Competing interests

B.J.D. is currently principal investigator or co-investigator on Novartis and Bristol-Myers Squibb clinical trials. His institution, OHSU, has contracts with these companies to pay for patient costs, nurse and data-manager salaries, and institutional overhead. He does not derive a salary, and his lab does not receive funds from these contracts. OHSU and B.J.D. have a financial interest in MolecularMD, a company that may have a commercial interest in this research and technology. This potential individual and institutional conflict of interest has been reviewed and managed by OHSU.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eide, C., Druker, B. Understanding cancer from the stem cells up. Nat Med 23, 656–657 (2017). https://doi.org/10.1038/nm.4353

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.4353

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation